MARK3 and cancer: Lastly, since highly downregulated DEGs such as PLAU, CTGF and CRYAB are known to promote angiogenesis in cancer, the in vivo tumor-suppressive effects of MARK3 were investigated via a mouse xenograft experiment using MARK3-inducible OVCAR3 cells.